Drägerwerk stock holds recent gains as guidance and order trends support valuation

Drägerwerk stock has been trading below its recent peak but remains supported by a visibly improved earnings profile, after the Lübeck-based medical and safety technology group (ISIN DE0005550636) swung back to profit in 2023 and confirmed its medium-term margin ambitions according to the companys annual report published on 7 March 2024. In that document, management pointed to better product mix, cost discipline, and easing supply chain constraints as the main drivers behind the stronger results for the year.

Revenue up around 13 percent in 2023

According to the 2023 annual report released on 7 March 2024, Drägerwerk generated revenue of about EUR 3.4 billion in 2023, compared with roughly EUR 3.0 billion in 2022, implying growth of around 13 percent year on year. The company highlighted in its commentary that both its medical and safety divisions contributed to the increase, with particular support from demand for intensive care ventilators, patient monitoring systems, and gas detection solutions.

The same report shows that Drägerwerk moved from a small net loss in 2022 to a positive net result in 2023, reporting net income of roughly EUR 40 million after posting a loss of approximately EUR 10 million in the prior year. This turnaround was mirrored in operating profitability: the group recorded an EBIT margin of about 3 percent for 2023, compared with roughly negative 1 percent in 2022, underscoring how pricing measures and lower freight and material costs helped offset ongoing wage inflation.

EBIT margin guidance between 2 and 5 percent

For 2024, Drägerwerk has guided for an EBIT margin in a corridor of roughly 2 to 5 percent, as stated in its outlook section of the 2023 annual report dated 7 March 2024. The company also indicated that it expects currency-adjusted revenue growth in the low to mid single-digit percentage range for 2024, building on the high base set in the previous year when pandemic-related demand normalized and standard business recovered.

Management emphasized that the margin guidance assumes continued progress in supply chain normalization, as well as further efficiency gains from ongoing transformation projects. For investors, the lower end of the EBIT margin range around 2 percent effectively acts as a buffer scenario, while the upper end around 5 percent would mark further improvement versus the 2023 level of about 3 percent, suggesting upside potential if order conversion and pricing remain favorable.

Hospital ventilation and safety products

Drägerwerk is best known for its life-support equipment in intensive care units, including ventilators, anesthesia workstations, and patient monitoring systems, alongside safety products like gas detection devices and personal protective equipment. In the 2023 reporting year, the medical division accounted for a bit more than half of group revenue, with sales of roughly EUR 1.9 billion, while the safety division contributed around EUR 1.5 billion.

The annual report for 2023 notes that demand for hospital ventilation equipment and related consumables remained resilient even as the acute pandemic phase faded, because hospitals continued to upgrade fleets and invest in higher-acuity care capacities. At the same time, Drägerwerk reported rising orders for industrial gas detection systems and respiratory protection, driven by regulatory requirements across sectors such as chemicals, oil and gas, and mining.

Drägerwerk stock and valuation context

On Xetra, Drägerwerk stock recently traded in a corridor around the mid double-digit euro range, with a 52-week high near EUR 60 and a 52-week low around EUR 40, based on public price data as of mid 2024. That range reflects how the market has repriced the shares in response to the earnings recovery and the more constructive guidance, while still discounting execution risks in the transformation and the sensitivity of hospital budgets to public financing conditions.

Using the 2023 revenue figure of about EUR 3.4 billion and a market capitalization in the low to mid single-digit billion euro range as reported by major exchanges in mid 2024, Drägerwerk trades on a price-to-sales multiple roughly in the low single digits. For investors, a key question is how quickly the company can move its EBIT margin toward the upper part of the 2 to 5 percent guidance band and eventually beyond, which would support higher valuation multiples if achieved sustainably.